Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525887 | 0.86 | HCAR3 (0.54) | SLC9A1KEAP1CYP2A6HCAR3HPGD | |
| SCHEMBL11388453 | 0.79 | POLB (0.48) | CYP2A6POLBMAPTKCNJ1NPC1 | |
| SCHEMBL6187604 | 0.78 | HCAR3 (0.50) | CYP2A6HCAR3HPGDSMN1; SMN2 | |
| SCHEMBL6185933 | 0.78 | SLC9A1 (0.53) | SLC9A1CYP2A6HCAR3POLBMAPT | |
| SCHEMBL22926199 | 0.75 | KDM1A (0.38) | SLC9A1KEAP1HCAR3HPGDPOLB | |
| SCHEMBL17103242 | 0.73 | SLC9A1 (0.57) | SLC9A1CYP2A6HCAR3MAPTNPC1 | |
| SCHEMBL3462849 | 0.73 | SLC9A1 (0.55) | SLC9A1KEAP1HCAR3NSD2CYP19A1 | |
| SCHEMBL2883687 | 0.73 | CISD1 (0.56) | HPGDNPC1RAB9A | |
| SCHEMBL2883684 | 0.73 | CISD1 (0.56) | HPGDNPC1RAB9A | |
| SCHEMBL17410806 | 0.72 | SLC9A1 (0.53) | SLC9A1KEAP1HCAR3NSD2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891136-B1 | 4-HETEROARYLCARBONYL-N-(PHENYL OR HETEROARYL)PIPERIDINE-1-CARBOXAMIDES AS INHIBITORS OF TANKYRASES | MERCK PATENT GMBH (DE) | 2023-07-19 | — | — | EP | disclosed |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| US-20220096454-A1 | CARBOXYLIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-03-31 | — | — | US | disclosed |
| EP-3891136-A1 | 4-HETEROARYLCARBONYL-N-(PHENYL OR HETEROARYL) PIPERIDINE-1-CARBOXAMIDES AS INHIBITORS OF TANKYRASES | Merck Patent GmbH (DE) | 2021-10-13 | — | — | EP | disclosed |
| CN-113166097-A | 4-heteroarylcarbonyl-N- (phenyl or heteroaryl) piperidine-1-carboxamides as tankyrase inhibitors | 默克专利股份公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021002986-A2 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020114892-A1 | 4-HETEROARYLCARBONYL-N-(PHENYL OR HETEROARYL) PIPERIDINE-1-CARBOXAMIDES AS INHIBITORS OF TANKYRASES | MERCK PATENT GMBH (DE) | 2020-06-11 | — | — | WO | disclosed |
| EP-1981871-B1 | HETEROCYCLYLALKYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-28 | — | — | EP | disclosed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| US-7846925-B2 | Azolidinone-vinyl fused-benzene derivatives | MERCK SERONO SA (CH) | 2010-12-07 | — | — | US | disclosed |
| EP-0232966-B1 | Process for the preparation of penem compounds and intermediates for this preparation | BEECHAM GROUP PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| US-5663354-A | Process for preparing enantiomerically pure 6-[(4-chlorophenyl) (1H-1,2,4-triazol-1-yl) methyl]-1-methyl-1H-benzotrizole | JANSSEN PHARMACEUTICA, N.V. (BE) | 1997-09-02 | — | — | US | disclosed |
| US-5587392-A | THERAPY FOR ESTROGEN DEPENDENT DISEASES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| EP-0408509-B1 | Substituted benzonitriles | CIBA GEIGY AG (CH) | 1996-03-06 | — | — | EP | disclosed |
| EP-0684235-A1 | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
| EP-0668861-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 6- (4-CHLOROPHENYL)(1H --TRIAZOL-1,2,4-TRIAZOL-1-YL)METHYL]-1-METHYL-1H --BENZOTRIAZOLE | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-08-30 | — | — | EP | disclosed |
| WO-1994011364-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 6-[(4-CHLOROPHENYL)(1H^_-TRIAZOL-1,2,4-TRIAZOL-1-YL)METHYL]-1-METHYL-1H^_-BENZOTRIAZOLE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-05-26 | — | — | WO | disclosed |
| US-5073574-A | TETRAZOLYL SUBSTITUTED BENZONITRILES AND ANTI-TUMOR USE THEREOF | CIBA-GEIGY CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0408509-A2 | Substituted benzonitriles | CIBA-GEIGY AG (CH) | 1991-01-16 | — | — | EP | disclosed |
| EP-0232966-A1 | Process for the preparation of penem compounds and intermediates for this preparation | BEECHAM GROUP PLC (GB) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096454-A1 | CARBOXYLIC ACID DERIVATIVES | IRAK1, TANK, TRAF6 | SLC9A1 3327/4885KEAP1 690/4885CYP2A6 1564/4885 |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | SLC9A1 4345/4885KEAP1 2972/4885CYP2A6 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.